Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel vs Docetaxel + Erlotinib in Relapsed EGFR Wild Type, ALK Negative Non-Squamous NSCLC
NCT02775006Phase 3Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung carcinoma (NSCLC), sponsored by Netherlands Cancer Institute. Started Oct 2016; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02775006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02775006.